AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...
Read moreEl trabajo de la Dra. Júlia Dulsat, realizado en IQS, está centrada en el uso de compuestos químicos que tienen el objetivo de detener el crecimiento celular canceroso y mejorar la efectividad del ...
Read moreDuring the day of March 21 from 10:00 a.m. to 4:00 p.m., Konexio Biotech had the honor of being present at the 'FIRST DAY OF INSPECTION AND CONTROL OF MEDICINES AEMPS & AEFI'
Read moreOryzon Genomics, S.A. announces that it has obtained the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation, and has consequently been registered in the Public Registry of INNOVAT...
Read moreOryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...
Read moreSOM Biotech, a clinical-stage drug discovery and development company based on a unique proprietary Artificial Intelligence platform (SOMAIPRO®), is pleased to announce that the recruitment of the Pha...
Read moreThis article explores the rise of biotech collaborations in pharma, the impact of M&A on the industry, the role of technology in biotech advancements, the regulatory challenges faced by pharma in its ...
Read moreBruno González-Zorn, asesor de la OMS, ofrece una charla en el IBFG para clausurar el proyecto MicroMundo, iniciativa de ciencia ciudadana en busca de nuevos compuestos
Read morePalobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD patients.
Read moreLaminar Pharma opens a new financing round of up to seven million euros. The objective is to finish financing the development of its drug LAM561 against the most aggressive and common brain cancer, gl...
Read moreIt Has been received “Intention to Grant” from the European Patent Office for the treatment of aggression and social withdrawal
Read more